Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study

BACKGROUND: RTOG 0625/ACRIN 6677 is a multicenter, randomized, phase II trial of bevacizumab with irinotecan or temozolomide in recurrent glioblastoma (GBM). This study investigated whether early posttreatment progression on FLAIR or postcontrast MRI assessed by central reading predicts overall surv...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Boxerman, Jerrold L., Zhang, Zheng, Safriel, Yair, Larvie, Mykol, Snyder, Bradley S., Jain, Rajan, Chi, T. Linda, Sorensen, A. Gregory, Gilbert, Mark R., Barboriak, Daniel P.
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2013
Предметы:
Clinical Investigations
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3688018/
https://ncbi.nlm.nih.gov/pubmed/23788270
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/not049
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы